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Purpose: The aim of this study was to assess the cost-effectiveness of confocal scan laser ophthalmoscopy (HRT II) and compare it with
scanning laser polarimetry (GDx) for diagnosing glaucoma.
Methods: A cost-effectiveness analysis was performed at two eye hospitals in Iran. The outcome was measured as the proportion of correctly
diagnosed patients based on systematic review and Meta analysis. Costs were estimated at two hospitals that used the HRT II (Noor Hospital) and
current diagnostic testing technology GDx (Farabi Hospital) from the perspective of the healthcare provider. The incremental cost-effectiveness
ratio (ICER) was estimated on the base scenario.
Results: Annual average costs were estimated as 12.70 USD and 13.59 USD per HRT II and GDx test in 2012, respectively. It was assumed that
80% of the maximum feasible annual tests in a work shift would be performed using HRT II and GDx and that the glaucoma-positive (Glþ )
proportion would be 56% in the referred eyes; the estimated diagnostic accuracies were 0.753 and 0.737 for GDx and HRT II, respectively. The
incremental cost-effectiveness ratio (ICER) was estimated at USD44.18 per additional test accuracy. In a base sensitivity sampling analysis, we
considered different proportions of Glþ patients (30%–85%), one or two work shifts, and efficiency rate (60%–100%), and found that the ICER
ranged from USD29.45to USD480.26, the lower and upper values in all scenarios.
Conclusion: Based on ICER, HRT II as newer diagnostic technology is cost-effective according to the World Health Organization threshold of
o1 Gross Domestic Product (GDP) per capita in Iran in 2012 (USD7228). Although GDx is more accurate and costly, the average cost-
effectiveness ratio shows that HRT II provided diagnostic accuracy at a lower cost than GDx.
& 2015 Iranian Society of Opthalmology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Glaucoma is considered the second-leading cause of
blindness worldwide.1 Although increased intraocular pressure
(IOP) was traditionally used as a defining feature of glaucoma,
the contemporary opinion reflects the fact that increased IOP/10.1016/j.joco.2015.10.002
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nder responsibility of the Iranian Society of Ophthalmology.is by no means pathognomonic of this condition.2 There is no
universally accepted definition of glaucoma2; therefore, it can
be considered a group of diseases that result in progressive
optic neuropathy with characteristic morphological changes at
the optic nerve head (ONH) and associated visual field defects
(the visual field has been defined as `that portion of space in
which objects are simultaneously visible to the steadily fixating
eye').2 In developed countries, glaucoma prevalence fluctuates
between 0.3 and 0.4 in people in the fifth decade of life.3 Some
population-based surveys in Iran showed that the prevalence of
glaucoma varies between 1.44% in the adult population in
Tehran to 4.4% in Yazd.4,5 It is estimated that more than 11lsevier B.V. This is an open access article under the CC BY-NC-ND license
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years.6 Improved methods for diagnosing glaucoma that can
provide rapid and repeatable examinations are urgently
required.7 Objective tests for diagnosing glaucoma are usually
based on the detection of structural and functional changes that
affect the ONH, peripapillary retinal nerve fibre layer (RNFL),
and visual field (VF) exam, respectively.8 Structural evalua-
tions of the ONH and peripapillary RNFL, using imaging
modalities such as optical coherence tomography, scanning
laser polarimetry(GDx), nerve fibre analysis, confocal scan-
ning laser ophthalmoscopy (CLSO), and Heidelberg retina
tomography (HRT), have become increasingly popular for the
early detection of glaucoma.8 Due to the importance of
structural changes when diagnosing glaucoma, this study
focused on HRT and GDx, in which HRT measured the
topography of the ONH and did not differentiate between
different layers of the retina, and GDx measured retardation,
which is a surrogate for RNFL thickness.9,10
Diagnostic technologies are more important than therapeutic
medical technologies because the results of diagnostic testing
can influence patient care and affect long-term outcomes due
to early disease detection.11 As a result, analyses of the
diagnostic test performance characteristics and the costs are
essential to decisions regarding the implementation of HRT or
GDx in Iran in light of budget limitations. In our previous
study, we assessed the diagnostic accuracies and clinical
effectiveness of confocal laser scanning ophthalmoscopy
(CSLO) and GDx via systematic review and meta-analysis.12
The current analysis will assess the cost-effectiveness of
CSLO-, also known as HRT, and GDx-based glaucoma
diagnoses at a public hospital in Iran from the perspective of
a healthcare provider.Methods
Study setting
A cost-effectiveness analysis was performed in order to
estimate and compare the costs per test accuracy of CLSO
(Heidelberg Engineering, HRT II) and GDx (Carl Zeiss
Meditec, GDxVCC) from the perspective of a healthcare
provider. Cost data were extracted from the central financial
databases of two hospitals specializing in eyes, using the top-
down allocation method. We calculated the direct medical cost
per test over a one-year time period. Because of the different
tariff per diagnostic test in private and public hospital, we
performed a cost accounting method in order to calculate real
cost per test in each hospital to reduce the impact of the tariff
difference on analysis.
Effectiveness data were collected from the results of a
systematic literature review and a meta-analysis based on test
accuracy.12 Clinical assessments by expert ophthalmologist(s),
based on visual field tests and assessments of the optic disc or
nerve fibre layer, were considered the reference standard test.
We calculated the incremental cost-effectiveness ratio as the
final outcome of this analysis.Collection of cost data
All cost data from a 12-month period were collected in May
2012. We considered the financial databases of two eye
hospitals in Tehran that used HRT II and GDx (Noor Eye
Hospital and Farabi Eye Hospital, respectively) as resources
for measurements. Direct medical cost categories included the
capital costs (device deployment) and recurrent costs (rent for
physical spaces, labour costs, consumable costs and main-
tenance, and overhead costs). Direct costs outside healthcare
and indirect costs such as opportunity costs were not con-
sidered. All costs were collected in Iranian Rials and converted
to US Dollars (exchange rate: USD1 = 12,226 Rials), using the
governmental exchange rates in 2012.
Unit cost valuation
The unit cost of diagnosis for each test was estimated
according to the top-down allocation method of all hospital
financial resources. In the top-down cost calculation method,
financial administration data from the healthcare provider is
the primary source for determining the unit costs per product.
Departmental costs of a department are derived from the cost-
accounting data and then assigned to the products or services
produced by the department. Top-down calculations can be
applied to cases of departments with relatively homogeneous
production. All costs can be obtained directly from the central
financial and production administration databases to calculate
the direct costs for any output.13
An ingredients technique was also implemented to provide
data that directly measured the maximum number of diagnostic
tests that could be done in one year at full performance and the
time required for each test, assuming a working hour shift.
Annualized equipment values were estimated with standard
procedures. HRT II and GDx purchase costs were determined
on the basis of inquiries to suppliers, assuming 10 years of
working life and a 5% depreciation rate, to annualize the
capital costs. The physical space cost was estimated from the
monthly rental price. Labour costs were allocated to each
personnel for each device per shift while considering the
annual salary and allowance. The maintenance cost of each
device was assumed to be 8% of the price index. Overhead
costs include costs of utility such as gas, electricity, and water
that was dedicated to the glaucoma department in each hospital
in this analysis. The amounts of utility items allocated to each
hospital were obtained from the financial record. The alloca-
tion of the quantities used by the clinic is based on the square
meter surface area. The time duration per examination was
estimated by inquiring about the time spent by the health
professionals performing the test, soliciting expert opinions,
and observing a limited number of examinations. The max-
imum possible numbers of examinations during each shift (as a
baseline) and during two shifts (for a sensitivity analysis) were
calculated while considering the specified times. However, the
efficiency percentage factor was used to modify the numbers
of tests performed during one year of practice. The total costs
of running the HRT II and GDx were divided by the number of
Table 2
Total cost of diagnostic test of glaucoma with HRT II and GDx (USD).
Item HRT II GDx
Rent, Lab 43,115 49,087
Labour (1 Shift) 28,448 26,595
Maintenance 3000 5572
Purchase cost (1st year) 3125 5803
Overhead 2866 5490
Training cost 3774 4854
Consumable/Test 42,509 38,258
Max. feasible tests/year 12,480 12,480
Efficiency 0.8 0.8
Number of tests/year 9984 9984
Total Costs for provider 126,838 137,788
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the unit cost per test.
Cost-effectiveness analysis model
In order to determine the cost-effectiveness ratio, the
effectiveness of each device was measured as the accuracy
test (True positive þ True negative)/(Number of tested) [Table
3]. In addition, the cost per test was calculated [Table 2]. The
actual baseline glaucoma prevalence was considered to be
56%.12 Next, the incremental cost-effectiveness ratio (ICER)
was calculated by the following formula:
ICER = (Average Cost HRT II
Average cost per test 12.70 13.59
Number of test per year = max feasible test * Efficiency
Table 1
Estimate a
Device
HRT II
GDx
Index price
Annual co
Cost/Year
Cost/Test = Average Cost GDx)/(Accuracy Test HRT II
 Accuracy Test GDx)Average cost per test = (Total cost)/Number of test per year.Sensitivity analysis
A sensitivity analysis was conducted on variables that were
uncertain and prone to change over time. The ICER was
estimated from the change in the number of tests per year, the
actual frequency of glaucoma, and the hospital tariffs for each
test, rather than the cost per test that was calculated [Table 4].
Result
Cost analysis
The unit cost of each diagnostic test was determined from the
number of possible tests per year and by calculating all health-care
provider costs. The cost analysis for each device is illustrated in
Table 2. The costs of the physical spaces for each device,
calculated on the basis of the monthly rental costs in the first
year, were estimated as 43 USD, 115 for HRT II and 49 USD,
087 for GDx. Labour costs were estimated on the basis of the
number of technicians who worked with each device (per work
shift) and from the gross salaries and other intensive payments that
were extracted from their pay-slips. We obtained values of 28
USD, 448 for HRT II and 26 USD, 595 for GDx. The difference
in labour cost is due to differences in the number of personnel and
their qualifications. Annual maintenance costs were estimated
from the index purchase price percentages that healthcare
providers must pay to corporate services and were found to be
3000 USD and 5572 USD for HRT II and GDx, respectively. The
monthly overhead costs for HRT II and GDx, based on thennualize cost of HRT II and GDX and cost per test (USD).
Price Year of acquisition Index Index price Annual
28,627 2007 1.31 37,501 3125
53,165 2007 1.31 69,646 5803
= Price * index
st of purchase = index price adjusted with 10 year with 5% depreciatio
= Annual cost of purchase þ Maintenance cost.
(Cost/Year)/(Test/Year).financial reports from 2 hospitals, were 2866 USD and 5490 USD,
respectively. The consumable costs per test were 4.3 USD and
3.8 USD for HRT II and GDx, respectively. We estimated the
annual consumable cost according to the maximum feasible
number of tests per year, while assuming the efficiency rate.
The total consumable costs during the first year were 42 USD, 509
for HRT II and 38 USD, 258 for GDx. Technicians and heath care
workers should receive training regarding the administration of
new diagnostic devices. The amounts of these costs were
estimated from the financial records of each hospital, training
materials, and workshop costs. The costs for this item were 3774
USD for HRT II and 4854 USD for GDx.
The prices of HRT II and GDx, based on surveys of medical
equipment companies and departments in each hospital, were 28
USD, 627 and 53 USD, 165, respectively. We calculated the price
index of each device based on the price index per year of
acquisition (2007) and price index of base year (=100) to obtain
the adjusted inflation rate. Next, we assumed a useful working life
of 10 years for each device, with a depreciation rate of 5%, to
estimate the annualized cost [Table 1]. Thus, the portion of capital
for each HRT II and GDx that should be considered for the first
year was estimated respectively at 3125 USD and 5803 USD.
The duration of each test with each device (including patient
preparation, examination, analysis, and printing of the results)
was 12 min, and therefore, the maximum possible numbers of
tests per device per year, assuming 8-h work shifts, 6 working
days per week, and 52 weeks per year, are 12,480 for one shift
(as a basis) and 23,712 for two shifts (including the timecost of purchase Maintenance Cost/Year Test/Year Cost/Test
3000 6125 9984 0.6
5571 11,375 9984 1.1
n rate.
Table 3
Comparison of effectiveness of the two diagnostic strategies.
Test Snn Spnn No. Test Prevalence Glþ Gl- True results False results Accuracy Cost per accuracy
HRT II 0.71 0.85 9984 0.56 5591 4393 7360 2624 0.737 17.40
GDx 0.80 0.89 9984 0.56 5591 4393 7527 2457 0.753 18.11
nSensitivity**Specificity.
Accuracy = True results/No. Test.
Cost per accuracy = Average cost per test/Accuracy.
Table 4
Summery of sensitivity analysis.
Item Base 1 2 5 6 7 8 Tariffs
Efficiency 0.8 0.6 1 0.8 0.8 0.8 1 0.8
Glaucoma
percent
56 56 56 30 85 56 85 56
Work shifts 1 1 1 1 1 2 2 1
Average cost
per HRT II
12.70 16.94 10.16 12.70 12.70 15.55 12.44 19.21
Average cost
per GDx
13.59 18.12 10.87 13.59 13.59 16.25 15.13 28.82
Test accuracy
for HRT II
0.73 0.73 0.73 0.78 0.68 0.73 0.68 0.73
Test accuracy
for GDx
0.75 0.75 0.75 0.79 0.71 0.75 0.71 0.75
Cost per
accuracy
HRT II
17.40 23.20 13.91 16.28 18.68 21.30 18.29 26.31
Cost per
accuracy
GDx
18.11 24.16 14.49 17.19 19.13 21.66 21.30 38.42
D cost 0.88 1.18 0.71 0.88 0.88 0.70 2.69 9.61
D accuracy 0.02 0.02 0.02 0.01 0.03 0.02 0.03 0.02
ICERa 44.18 59.00 35.50 88.35 29.45 35.00 89.67 480.26
D cost = Cost per accuracy HRT II – Cost per accuracy GDx.
D accuracy = Test Accuracy for HRT II – Test Accuracy for GDx.
ICER = D cost/D accuracy.
aICER = Incremental cost effectiveness ratio.
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(80% of possible tests run per year), the number of possible
tests per year is 9984. The average total costs per test were
calculated as 12.70 USD for HRT II and 13.59 USD for GDx.
The summary of the diagnostic evaluation costs for HRT II
and GDx while considering the basic assumptions is repre-
sented in Table 2.
Effectiveness of two diagnostic strategies
Effectiveness of each diagnostic test was calculated based
on our recent paper.12 A meta-analysis was conducted for
pooling data to compare Heidelberg Retina Tomograph (HRT
II) with scanning laser polarimetry (GDx) with the criteria of
``visual field defect'' and ``changes of nerve fibre layer'' as the
gold standard.
Indices of accuracy of diagnostic test and its comparator
including positive likelihood ratio (PLR), negative likelihood
ratio (NLR), diagnostic odds ratio (DOR), true test results(TS), sensitivity (Sn), and specificity (Sp) were extracted from
the primary studies. In total, 15 studies on 4776 eyes
(including 2408 non-glaucomatous and 2369 glaucomatous)
had assessed diagnostic accuracy of HRT II. There was
considerable heterogeneity between results of the studies (Q
= 43.29, P o 0.001, I2 = 67%), and pooled estimate of DOR
(95% CIs) was 11.84 (9.97–14.06) for HRT II. There were
5 qualified studies on the 648 eyes (254 glaucomatous and 394
non-glaucomatous) for GDx concurrent with at least one of the
editions of HRT. There was heterogeneity between results of
these studies (Q = 5.61, P = 0.23, I2 = 28.7%). Diagnostic
odds ratios (95% CIs) were 21.33 (13.56–33.55) for GDx by
random model. True results were 7360 and 7527 for HRT II
and GDx, respectively [Table 3]. The results of egger test also
show that there is no significant publication bias on the result
of HRT II and GDx.12
Determining the incremental cost-effectiveness ratio
The average cost difference between the two methods (Cost
HRTII  Cost GDx), assuming among others 9984 tests in the
first year, was calculated to be 0.88 USD. The test accuracy
difference between the two methods (TA HRTII  TA GDx),
given the characteristics of the diagnostic tests, was estimated
to be 0.02; therefore, at the baseline, the ICER of HRT II to
GDx was calculated as 44.18 USD based on ICER formula.
Sensitivity analysis
In a sampling base sensitivity analysis, ICER was estimated by
changing the mean cost and test accuracy. We varied the mean cost
by changing the efficiency percentage and the number of working
shifts. In addition, in the last scenario, we used hospital tariffs
instead of the estimated costs per test; furthermore, the accuracy per
test was changed by changing the glaucoma percentage for each
scenario [Table 4]. If we used the hospital tariff-based costs, which
were 19.21 USD and 28.82 USD for HRT II and GDx,
respectively, instead of the estimated costs from this project, the
ICER is 480.26 USD (other assumptions remain constant).
Discussion
Because diagnostic tests affect short-term outcomes more than
long-term outcomes, related assessments are more complicated
than evaluating the therapeutic technologies.14 Confocal scanning
microscopy, as applied in the HRT system, is a safe system
M. Mokhtari-Payam et al. / Journal of Current Ophthalmology 27 (2015) 16–2020without any important reports of side effects in the users and
patients.15 The glaucoma diagnostic accuracy of the GDx system
is acceptable and higher than that of HRT II. HRT II-based
glaucoma diagnoses had a lower cost (12.70 USD) but a lower
effectiveness (0.7372) than GDx-based diagnoses. In fact, a GDx-
based diagnostic strategy is both more effective and more costly.
In this circumstance, the World Health Organization (WHO)
guidelines recommend that when a strategy is both more effective
and more costly, the dominance principle provides no guidance.
The decision-maker must decide if the greater effectiveness
justifies the greater achievement cost.12 In addition, the average
cost-effectiveness ratio of HRT II (17.40 USD) is lower than that
of GDx (18.11 USD) in the baseline case analyses and in all
scenarios in the sensitivity analyses. Given the difference in
diagnostic test accuracy between GDx and HRT II (0.02) and the
Average Cost Effectiveness Ratio (ACER) result, health-care
providers could implement a new intervention (HRT II) that
would detect acceptable numbers of glaucoma cases at a lower
cost than that of GDx.
The ICER of HRT II to GDx was estimated at approximately
44.18 USD with basic assumptions. If we concentrate solely on
the ICER, the results imply that this intervention is cost-effective
according to the WHO threshold, which is o1 GDP per capita in
Iran in 2012 (7228 USD). The interpretation is that the ICER
value is less than the national threshold, and therefore, imple-
mentation of the new technology will be recommended because it
will be more efficient. The new technology will detect more cases,
and thus, it will help to treat more episodes.
However, in an older study that was designed to evaluate the
cost-effectiveness of open-angle glaucoma screening in the general
population of Quebec, scanning confocal microscopy was not
considered an effective tool for this intervention.11 In addition,
Kass et al16 reported uncertainty regarding the use CLSO for
diagnosing glaucoma. Also, Kwartz et al2 showed poor agreement
with regard to glaucoma detection between HRT and GDx. In
summary, no single modality has sufficient diagnostic precision to
be used in isolation, and neither HRT nor GDx should be viewed
as a replacement for visual field examination.
There are some limitations in this study. For example, the
number of tests is less than the maximum. It may be possible
in the future to show more valuable objective test results in
comparison to an examination by an ophthalmologist through
cohort study follow-ups. This study has also not accounted for
analyses by age, sex, and ethnicity that may affect cost-
effectiveness ratios.
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